Skip to main content Help with accessibility Skip to main navigation

All Guidance

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Treatment of active rheumatoid arthritis and active psoriatic arthritis

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Pending
Date Posted: 11 - March - 2021
BNF chapter: Infection
For the treatment of pneumonia or complicated skin and soft tissue infections on the recommendation of a microbiologist when used as a 10-14-day course 

**Please refer to attached prescriber information sheet for more detail prior to prescribing**

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 20 - July - 2022
BNF chapter: Cardiovascular system

LSCMMG endorses the 'Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD' produced by the Accelerated Access Collaborative Clinical Subgroup

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2014
BNF chapter: Central nervous system

Licensed Indications

  1. In the management of acute mania or hypomanic episodes
  2. In the management of episodes of recurrent depressive disorders where treatment with other antidepressants has been unsuccessful
  3. In the prophylaxis against bipolar affective disorders
  4. Control of aggressive behaviours of intentional self-harm.
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - March - 2018

This guidance has been produced to facilitate the safe prescribing of LMWHs in primary care. It provides an overview of points to be considered when initiating LMWHs and when transferring prescribing responsibilities to or from another organisation.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018
BNF chapter: Central nervous system

This is a summary document intended for Primary Care, taken from a more comprehensive document ‘Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) in Primary and Secondary Care. This document should be accessed for additional resources such as the Leaflet for Care Home Staff, assessment forms and flow chart for responding to BPSD.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018
BNF chapter: Central nervous system

Information contained within this document is largely taken from the PrescQIPP toolkit ‘Reducing Antipsychotics in Dementia and documents available on the Alzheimer’s Society website.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2017

This guideline comprises a flow chart outlining a stepwise approach to the management of psoriasis in adults and in children and young people. The guideline also includes relevant treatment review periods and referral criteria.

Not adopted
Not adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
BNF chapter: Central nervous system
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 14 - June - 2022
BNF chapter: Central nervous system
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted

Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease

N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

This protocol only applies to the unlicensed indications listed below. Transplant protocols should be followed for licensed indications.

Unlicensed: Severe rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, connective tissue diseases with severe / organ-threatening manifestations, interstitial lung disease (not to be used in idiopathic pulmonary fibrosis IPF), vasculitidies, as maintenance post cyclophosphamide in patients for whom azathioprine is contra-indicated or is inappropriate.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - August - 2019
BNF chapter: Infection

For Nebulisation in Adult Patients with Non-Cystic Fibrosis Bronchiectasis

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - November - 2022
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2017
BNF chapter: Eye
  • Age related Macular Degeneration   

  • Diabetic Macular Oedema 

  • Macular Oedema secondary to Central Retinal Vein Occlusion

  • Macular Oedema secondary to Branch Retinal Vein Occlusion

  • CNV associated with pathological myopia

  • Vitreomacular Traction

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018
BNF chapter: Blood and Nutrition
**This Guideline is currently under review. For further information please click here**

The purpose of oral nutritional supplementation (ONS) is to supplement food intake, not replace it and their use does not remove the need to manage the underlying condition responsible for the patient’s poor appetite. It is important to ensure that prescribing is both appropriate for the patient and that the treatment length is such that waste is minimised.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Prescribing request from out-of-area specialists to Lancashire GPs where there is an inconsistency with the recommended local and out-of-area colour classification

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2019

In developing local commissioning policies, the CCG will commission treatments or services which accord with all of the following principles:

  • Appropriateness
  • Effectiveness
  • Cost-effectiveness
  • Ethics
  • Affordability

A number of treatments which should be considered a LOW PRIORITY are detailed within this policy

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 15 - December - 2021
BNF chapter: Genito-urinary system
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted

Guidance on consensus approaches to managing Palliative Care Symptoms